This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016]
Overall distribution
Tissue specific distribution
Expression restricted in 8 cancer type(s)
Overall distribution
Tissue specific distribution
Gscore (Amp):
0.52
Gscore (Del):
0.00
Recurrently amplified in 4 cancer type(s)
Overall distribution
Tissue specific distribution
Mscore:
0.31 (Driver)
Recurrently mutated in 1 cancer type(s)
Overall
Tissue specific
Total fusion occurrence:
20 (Driver)
Fusions detected in 10 cancer type(s)
Overall
Tissue specific
STRONGLY SELECTIVE
Functional class:
Kinase (protein kinase)
JensenLab PubMed score:
2013.66 (Percentile rank: 97.90%)
PubTator score:
1522.99 (Percentile rank: 97.67%)
Target development/druggability level:
TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action.
Tractability (small molecule):
Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets
Tractability (antibody):
Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets
